Publications by authors named "Orly Avnery"

Claim this Profile
V
Vitamin K Antagonist Anticoagulation in Antiphospholipid Syndrome: Time in Therapeutic Range and Clinical Outcomes.
Keren Meir, Stanley Niznik, Orly Avnery, Adi Zoref-Lorenz, Nancy Agmon-Levin

Am J Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heart valve disease in primary antiphospholipid syndrome.
Stanley Niznik, Micha J Rapoport, Orly Avnery, Mona Kidon, Ronen Shavit

Rheumatology (Oxford)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombosis in multiple myeloma: mechanisms, risk assessment and management.
Osnat Jarchowsky, Orly Avnery, Martin H Ellis

Leuk Lymphoma· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnicity and Antiphospholipid Syndrome in Israel.
Stanley Niznik, Micha J Rapoport, Orly Avnery, Martin H Ellis, Soad Hajyahia

Arthritis Care Res (Hoboken)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome-Multicenter, Real-Life Long-Term Follow-Up.
Stanley Niznik, Micha J Rapoport, Orly Avnery, Aharon Lubetsky, Soad Haj Yahia

Front Immunol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome.
Stanley Niznik, Micha J Rapoport, Orly Avnery, Aharon Lubetsky, Ronen Shavit

Front Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decision-Making in the Management of Venous Thromboembolism.
Martin H Ellis, Orly Avnery

Am J Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillation.
Ronen Arbel, Ruslan Sergienko, Ariel Hammerman, Sari Dotan-Greenberg, Erez Batat, Orly Avnery

Heart· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation.
Ronen Arbel, Ruslan Sergienko, Ariel Hammerman, Sari Greenberg-Dotan, Erez Batat, Orly Avnery

Am J Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Genetic Origin? Purpura Fulminans.
Orly Avnery, Gili Kenet, Martin H Ellis

Am J Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[PRACTICAL ADVICE FOR THE APPROPRIATE USE OF DIRECT ORAL ANTICOAGULANTS].
Martin H Ellis, Shirley Shapira, Orly Avnery

Harefuah· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study.
Martin H Ellis, Sari Greenberg Dotan, Ariel Hammerman, Erez Battat, Estela Derazne, Orly Avnery

Thromb Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis